Oncolytics Biotech Files Routine 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Apr 25, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateApr 25, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, sec-filing, foreign-private-issuer

TL;DR

ONCO files routine 6-K, no major news, just standard reporting.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on April 25, 2024, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is in the Pharmaceutical Preparations industry and will file its annual reports under Form 20-F. This filing does not appear to contain specific financial updates or material events beyond its routine reporting status.

Why It Matters

This filing indicates Oncolytics Biotech Inc. is fulfilling its reporting obligations as a foreign private issuer, which is standard for companies trading on US exchanges but based internationally.

Risk Assessment

Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of April 2024.

Which form will Oncolytics Biotech Inc. use for its annual reports?

Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.

Where are Oncolytics Biotech Inc.'s principal executive offices located?

The principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

What is the Standard Industrial Classification code for Oncolytics Biotech Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Oncolytics Biotech Inc.?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-04-25 12:07:25

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date April 25, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing